Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | July 27, 2012

Global Warming and Alzheimer’s Disease

PET images produced using florbetapir, which highlights beta-amyloid plaques, show the brains of a cognitively normal subject (top left); an amyloid-positive patient with Alzheimers disease (top right); a patient with mild cognitive impairment (bottom left) and a patient with mild cognitive impairment who progressed to dementia during a multi-center 18-month study (bottom right). Image courtesy of the journal Neurology

When I was a kid, living in a mid-size Wisconsin town, my family would drive the mile or so from our home to the Lake Michigan shore to escape the occasional oppressive heat of summer.  The deep lake waters cooled the air. The hour or two we spent at its shore on hot July and August days gave us the break we needed to face the rest of the day in our house.

My mind returned to that time after seeing a political cartoon dismissing those who blame the searing heat across our nation on global warming. “We used to call them heat waves,” said the tag line of the cartoon showing sweltering heat and a newspaper headline blaming global warming. That got me thinking.

When I was young, senility was a natural consequence of getting old.  When science tried to change that way of thinking, Alzheimer’s disease was dismissed as “old timer’s” disease.  It was medical imaging that turned the tide, visualizing a disease process that couldn’t previously be seen.

Positron emission tomography (PET) images show amyloid plaques accumulating in the brains of patients with Alzheimer’s disease. Research published earlier this month found that early detection of these plaques could help guide patient management and possibly the development of new therapies for patients with the disease (http://www.neurology.org/content/early/2012/07/11/WNL.0b013e3182661f74.short?rss=1). The researchers used a PET agent called florbetapir. Not long ago, the U.S. Food & Drug Administration (FDA) approved florbetapir, commercially dubbed Amyvid by its developer Eli Lilly, making it the first commercial imaging agent for visualizing amyloid plaques and, therefore, diagnosing Alzheimer’s disease.

The company, as seen in its FDA-approved labeling, is careful not to claim too much. A positive result using Amyvid “does not establish a diagnosis of Alzheimer’s disease,” according to the labeling. It can be used, however, to rule out other dementias, as only Alzheimer’s disease is associated with the presence of amyloid plaques.  The distinction is a fine point, best appreciated in scientific circles, where the community arrives at and embraces new ideas only after taking a series of cautious steps.

So it is with global warming. What we once believed were heat waves may have been the early signs of global change, signs that were not recognized for what they were, just as senility was viewed as an inevitable part of life rather than a disease.

Medical imaging is providing visual evidence of the underlying disease process. The use of Amyvid and the rival drugs that follow in its wake – GE and Bayer are known to be working on similar products – will increase as reimbursement for their use becomes available.

Sure to make an even greater impact will be effective treatments for Alzheimer’s disease.  Amyvid and other such agents may promote the development of such treatments. By providing the means for diagnosis, they make it easier to identify patient populations for testing experimental therapies, just as they may provide a baseline through the visualization of amyloid plaques for assessing the effectiveness of these therapies. 

Future progress, therefore, depends on developing an understanding of the underlying problems that can only be gained through scientific progress, regardless of whether we are battling senility or heat waves. Understanding the complex factors involved can be confounding. But to dismiss efforts aimed at doing so – or worse yet, denying the presence of disease or environmental change – is self-defeating.

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Charles Ananian, M.D.

Charles Ananian, M.D.

Sponsored Content | Case Study | Digital Radiography (DR) | November 07, 2018
Whether it’s a premature baby or a critically ill child, treating little patients is a huge responsibility.
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....